{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:13:17Z","timestamp":1788257597108,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Second Century Fund"},{"name":"The 90th Anniversary of Chulalongkorn University Fund"},{"name":"The 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship"},{"name":"THE 90TH Anniversary of Chulalongkorn University Scholarship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glucose 6-phosphate dehydrogenase (G6PD) and pyruvate kinase (PKLR) deficiencies are common causes of erythrocyte haemolysis in the presence of antimalarial drugs such as primaquine and tafenoquine. The present study aimed to elucidate such an association by thoroughly investigating the haematological indices in malaria patients with <jats:italic>G6PD<\/jats:italic> and <jats:italic>PKLR<\/jats:italic><jats:sup><jats:italic>R41Q<\/jats:italic><\/jats:sup> variants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Blood samples from 255 malaria patients from Thailand, Myanmar, Laos, and Cambodia were collected to determine haematological profile, G6PD enzyme activity and <jats:italic>G6PD<\/jats:italic> deficiency variants. The multivariate analysis was performed to investigate the association between anaemia and <jats:italic>G6PD Mahidol<\/jats:italic><jats:sup><jats:italic>G487A<\/jats:italic><\/jats:sup>, the most common mutation in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The prevalence of G6PD deficiency was 11.1% (27\/244) in males and 9.1% (1\/11) in female. The MAFs of the <jats:italic>G6PD Mahidol<\/jats:italic><jats:sup><jats:italic>G487A<\/jats:italic><\/jats:sup> and <jats:italic>PKLR<\/jats:italic><jats:sup><jats:italic>R41Q<\/jats:italic><\/jats:sup> variants were 7.1% and 2.6%, respectively. Compared with patients with <jats:italic>wildtype G6PD<\/jats:italic> after controlling for haemoglobinopathies, G6PD-deficient patients with hemizygous and homozygous <jats:italic>G6PD Mahidol<\/jats:italic><jats:sup><jats:italic>G487A<\/jats:italic><\/jats:sup> exhibited anaemia with low levels of haemoglobin (11.16\u2009\u00b1\u20092.65\u00a0g\/dl, <jats:italic>p<\/jats:italic>\u2009=\u20090.041). These patients also exhibited high levels of reticulocytes (3.60%). The median value of G6PD activity before treatment (Day 0) was significantly lower than that of after treatment (Day 28) (5.51\u2009\u00b1\u20092.54 U\/g Hb vs. 6.68\u2009\u00b1\u20092.45 U\/g Hb; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Reticulocyte levels on Day 28 were significantly increased compared to that of on Day 0 (2.14\u2009\u00b1\u20090.92% vs 1.57\u2009\u00b1\u20091.06%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). <jats:italic>PKLR<\/jats:italic><jats:sup><jats:italic>R41Q<\/jats:italic><\/jats:sup> had no correlation with anaemia in malaria patients. The risk of anaemia inpatients with <jats:italic>G6PD<\/jats:italic><jats:italic>Mahidol<\/jats:italic><jats:sup><jats:italic>G487A<\/jats:italic><\/jats:sup> was higher than <jats:italic>wildtype<\/jats:italic> patients (OR\u2009=\u20093.48, CI% 1.24\u20139.75, <jats:italic>p<\/jats:italic>\u2009=\u20090.018). Univariate and multivariate analyses confirmed that <jats:italic>G6PD<\/jats:italic><jats:italic>Mahidol<\/jats:italic><jats:sup><jats:italic>G487A<\/jats:italic><\/jats:sup> independently associated with anaemia (&lt;\u200911\u00a0g\/dl) after adjusted by age, gender, <jats:italic>Plasmodium<\/jats:italic> species, parasite density, <jats:italic>PKLR<\/jats:italic><jats:sup><jats:italic>R41Q<\/jats:italic><\/jats:sup>, and haemoglobinopathies (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This study revealed that malaria patients with <jats:italic>G6PD Mahidol<\/jats:italic><jats:sup><jats:italic>G487A<\/jats:italic><\/jats:sup>, but not with <jats:italic>PKLR<\/jats:italic><jats:sup><jats:italic>R41Q<\/jats:italic><\/jats:sup>, had anaemia during infection. As a compensatory response to haemolytic anaemia after malaria infection, these patients generated more reticulocytes. The findings emphasize the effect of host genetic background on haemolytic anaemia and the importance of screening patients for erythrocyte enzymopathies and related mutations prior to anti-malarial therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04267-7","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T03:27:24Z","timestamp":1661830044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Haematological profile of malaria patients with G6PD and PKLR variants (erythrocytic enzymopathies): a cross-sectional study in Thailand"],"prefix":"10.1186","volume":"21","author":[{"given":"Punchalee","family":"Mungkalasut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patcharakorn","family":"Kiatamornrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Watcharapong","family":"Jugnam-Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srivicha","family":"Krudsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonlarp","family":"Cheepsunthorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalisa Louicharoen","family":"Cheepsunthorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"4267_CR1","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1182\/blood.V95.11.3585","volume":"95","author":"E Beutler","year":"2000","unstructured":"Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood. 2000;95:3585\u20138.","journal-title":"Blood"},{"key":"4267_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64\u201374.","journal-title":"Lancet"},{"key":"4267_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bcmd.2012.01.001","volume":"48","author":"A Minucci","year":"2012","unstructured":"Minucci A, Moradkhani K, Hwang MJ, Zuppi C, Giardina B, Capoluongo E. Glucose-6-phosphate dehydrogenase (G6PD) mutations database: review of the \u201cold\u201d and update of the new mutations. Blood Cells Mol Dis. 2012;48:154\u201365.","journal-title":"Blood Cells Mol Dis"},{"key":"4267_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.hoc.2015.11.006","volume":"30","author":"L Luzzatto","year":"2016","unstructured":"Luzzatto L, Nannelli C, Notaro R. Glucose-6-phosphate dehydrogenase deficiency. Hematol Oncol Clin North Am. 2016;30:373\u201393.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4267_CR5","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1178849","volume":"326","author":"C Louicharoen","year":"2009","unstructured":"Louicharoen C, Patin E, Paul R, Nuchprayoon I, Witoonpanich B, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. Science. 2009;326:1546\u20139.","journal-title":"Science"},{"key":"4267_CR6","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.62448","volume":"10","author":"GR Awab","year":"2021","unstructured":"Awab GR, Aaram F, Jamornthanyawat N, Suwannasin K, Pagornrat W, et al. Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria. Elife. 2021;10: e62448.","journal-title":"Elife"},{"key":"4267_CR7","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1475-2875-12-391","volume":"12","author":"GJ Domingo","year":"2013","unstructured":"Domingo GJ, Satyagraha AW, Anvikar A, Baird K, Bancone G, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Malar J. 2013;12:391.","journal-title":"Malar J"},{"key":"4267_CR8","unstructured":"WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale: Policy brief. Geneva: World Health Organization; 2016. Contract No.: WHO\/HTM\/GMP\/2016.9."},{"key":"4267_CR9","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/S2666-5247(21)00356-6","volume":"3","author":"W Stone","year":"2022","unstructured":"Stone W, Mahamar A, Smit MJ, Sanogo K, Sinaba Y, et al. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial. Lancet Microbe. 2022;3:e336\u201347.","journal-title":"Lancet Microbe"},{"key":"4267_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/1475-2875-12-418","volume":"12","author":"RE Howes","year":"2013","unstructured":"Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418.","journal-title":"Malar J"},{"key":"4267_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/adc.44.235.373","volume":"44","author":"RH Fung","year":"1969","unstructured":"Fung RH, Keung YK, Chung GS. Screening of pyruvate kinase deficiency and G6PD deficiency in Chinese newborn in Hong Kong. Arch Dis Child. 1969;44:373\u20136.","journal-title":"Arch Dis Child"},{"key":"4267_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/ajh.2830200206","volume":"20","author":"ZL Wu","year":"1985","unstructured":"Wu ZL, Yu WD, Chen SC. Frequency of erythrocyte pyruvate kinase deficiency in Chinese infants. Am J Hematol. 1985;20:139\u201344.","journal-title":"Am J Hematol"},{"key":"4267_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1365-2141.2005.05527.x","volume":"130","author":"A Zanella","year":"2005","unstructured":"Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol. 2005;130:11\u201325.","journal-title":"Br J Haematol"},{"key":"4267_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ng1260","volume":"35","author":"G Min-Oo","year":"2003","unstructured":"Min-Oo G, Fortin A, Tam MF, Nantel A, Stevenson MM, Gros P. Pyruvate kinase deficiency in mice protects against malaria. Nat Genet. 2003;35:357\u201362.","journal-title":"Nat Genet"},{"key":"4267_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144555","volume":"10","author":"R van Bruggen","year":"2015","unstructured":"van Bruggen R, Gualtieri C, Iliescu A, Louicharoen Cheepsunthorn C, Mungkalasut P, et al. Modulation of malaria phenotypes by pyruvate kinase (PKLR) variants in a Thai population. PLoS ONE. 2015;10: e0144555.","journal-title":"PLoS ONE"},{"key":"4267_CR16","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2018.015","volume":"10","author":"S Para","year":"2018","unstructured":"Para S, Mungkalasut P, Chanda M, Nuchprayoon I, Krudsood S, Cheepsunthorn CL. An observational study of the effect of hemoglobinopathy, alpha thalassemia and hemoglobin E on P. vivax parasitemia. Mediterr J Hematol Infect Dis. 2018;10: e2018015.","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"4267_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s10038-007-0217-3","volume":"53","author":"I Nuchprayoon","year":"2008","unstructured":"Nuchprayoon I, Louicharoen C, Charoenvej W. Glucose-6-phosphate dehydrogenase mutations in Mon and Burmese of southern Myanmar. J Hum Genet. 2008;53:48\u201354.","journal-title":"J Hum Genet"},{"key":"4267_CR18","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood.V95.1.360","volume":"95","author":"SS Chong","year":"2000","unstructured":"Chong SS, Boehm CD, Higgs DR, Cutting GR. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. Blood. 2000;95:360\u20132.","journal-title":"Blood"},{"key":"4267_CR19","first-page":"306","volume":"40","author":"K Tachavanich","year":"2009","unstructured":"Tachavanich K, Viprakasit V, Chinchang W, Glomglao W, Pung-Amritt P, Tanphaichitr VS. Clinical and hematological phenotype of homozygous hemoglobin E: revisit of a benign condition with hidden reproductive risk. Southeast Asian J Trop Med Public Health. 2009;40:306\u201316.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"4267_CR20","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood.V82.11.3503.3503","volume":"82","author":"L Makonkawkeyoon","year":"1993","unstructured":"Makonkawkeyoon L, Sanguansermsri T, Asato T, Nakashima Y, Takei H. Rapid detection of chain termination mutations in the alpha 2 globin gene. Blood. 1993;82:3503\u20134.","journal-title":"Blood"},{"key":"4267_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12936-018-2509-9","volume":"17","author":"NJ White","year":"2018","unstructured":"White NJ. Anaemia and malaria. Malar J. 2018;17:371.","journal-title":"Malar J"},{"key":"4267_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006230","volume":"12","author":"J Recht","year":"2018","unstructured":"Recht J, Ashley EA, White NJ. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis. 2018;12: e0006230.","journal-title":"PLoS Negl Trop Dis"},{"key":"4267_CR23","volume-title":"World malaria report 2015","author":"WHO","year":"2015","unstructured":"WHO. World malaria report 2015. Geneva: World Health Organization; 2015."},{"key":"4267_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116063","volume":"9","author":"G Bancone","year":"2014","unstructured":"Bancone G, Chu CS, Somsakchaicharoen R, Chowwiwat N, Parker DM, et al. Characterization of G6PD genotypes and phenotypes on the northwestern Thailand-Myanmar border. PLoS ONE. 2014;9: e116063.","journal-title":"PLoS ONE"},{"key":"4267_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40249-016-0130-0","volume":"5","author":"M Kotepui","year":"2016","unstructured":"Kotepui M, Uthaisar K, PhunPhuech B, Phiwklam N. Prevalence and hematological indicators of G6PD deficiency in malaria-infected patients. Infect Dis Poverty. 2016;5:36.","journal-title":"Infect Dis Poverty"},{"key":"4267_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/humu.9010","volume":"19","author":"I Nuchprayoon","year":"2002","unstructured":"Nuchprayoon I, Sanpavat S, Nuchprayoon S. Glucose-6-phosphate dehydrogenase (G6PD) mutations in Thailand: G6PD Viangchan (871GA) is the most common deficiency variant in the Thai population. Hum Mutat. 2002;19:185.","journal-title":"Hum Mutat"},{"key":"4267_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008697","volume":"14","author":"B Ley","year":"2020","unstructured":"Ley B, Kibria MG, Khan WA, Auburn S, Phru CS, et al. Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts. Bangladesh PLoS Negl Trop Dis. 2020;14: e0008697.","journal-title":"Bangladesh PLoS Negl Trop Dis"},{"key":"4267_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12936-019-2652-y","volume":"18","author":"G Bancone","year":"2019","unstructured":"Bancone G, Menard D, Khim N, Kim S, Canier L, et al. Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion. Malar J. 2019;18:20.","journal-title":"Malar J"},{"key":"4267_CR29","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.3390\/ijms17122069","volume":"17","author":"S G\u00f3mez-Manzo","year":"2016","unstructured":"G\u00f3mez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, Serrano-Posada H, Ortega-Cuellar D, et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. Int J Mol Sci. 2016;17:2069.","journal-title":"Int J Mol Sci"},{"key":"4267_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/j.1460-2075.1988.tb02827.x","volume":"7","author":"D Toniolo","year":"1988","unstructured":"Toniolo D, Martini G, Migeon BR, Dono R. Expression of the G6PD locus on the human X chromosome is associated with demethylation of three CpG islands within 100 kb of DNA. EMBO J. 1988;7:401\u20136.","journal-title":"EMBO J"},{"key":"4267_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00439-002-0783-6","volume":"111","author":"GA Garinis","year":"2002","unstructured":"Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet. 2002;111:115\u201327.","journal-title":"Hum Genet"},{"key":"4267_CR32","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0027-5107(96)00222-9","volume":"374","author":"S Sanders","year":"1997","unstructured":"Sanders S, Smith DP, Thomas GA, Williams ED. A glucose-6-phosphate dehydrogenase (G6PD) splice site consensus sequence mutation associated with G6PD enzyme deficiency. Mutat Res. 1997;374:79\u201387.","journal-title":"Mutat Res"},{"key":"4267_CR33","unstructured":"Updating the WHO G6PD classification of variants and the International Classification of Diseases, 11th Revision (ICD-11) [Internet]. Malaria Policy Committee Meeting. 2019. Accessed Feb 2020."},{"key":"4267_CR34","first-page":"581","volume":"39","author":"W Leowattana","year":"2008","unstructured":"Leowattana W, Krudsood S, Tangpukdee N, Brittenham G, Looareesuwan S. Defective erythropoietin production and reticulocyte response in acute Plasmodium falciparum malaria-associated anaemia. Southeast Asian J Trop Med Public Health. 2008;39:581\u20138.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"4267_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1046\/j.1365-2141.1997.82654.x","volume":"97","author":"JA Kurtzhals","year":"1997","unstructured":"Kurtzhals JA, Rodrigues O, Addae M, Commey JO, Nkrumah FK, Hviid L. Reversible suppression of bone marrow response to erythropoietin in Plasmodium falciparum malaria. Br J Haematol. 1997;97:169\u201374.","journal-title":"Br J Haematol"},{"key":"4267_CR36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1600-0609.1997.tb01690.x","volume":"59","author":"AM el Hassan","year":"1997","unstructured":"el Hassan AM, Saeed AM, Fandrey J, Jelkmann W. Decreased erythropoietin response in Plasmodium falciparum malaria-associated anaemia. Eur J Haematol. 1997;59:299\u2013304.","journal-title":"Eur J Haematol"},{"key":"4267_CR37","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1016\/j.ijpara.2004.10.008","volume":"34","author":"KH Chang","year":"2004","unstructured":"Chang KH, Stevenson MM. Malarial anaemia: mechanisms and implications of insufficient erythropoiesis during blood-stage malaria. Int J Parasitol. 2004;34:1501\u201316.","journal-title":"Int J Parasitol"},{"key":"4267_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4269\/ajtmh.1996.54.280","volume":"54","author":"H Burgmann","year":"1996","unstructured":"Burgmann H, Looareesuwan S, Kapiotis S, Viravan C, Vanijanonta S, et al. Serum levels of erythropoietin in acute Plasmodium falciparum malaria. Am J Trop Med Hyg. 1996;54:280\u20133.","journal-title":"Am J Trop Med Hyg"},{"key":"4267_CR39","doi-asserted-by":"publisher","first-page":"547","DOI":"10.4269\/ajtmh.1995.53.547","volume":"53","author":"GD Burchard","year":"1995","unstructured":"Burchard GD, Radloff P, Philipps J, Nkeyi M, Knobloch J, Kremsner PG. Increased erythropoietin production in children with severe malarial anaemia. Am J Trop Med Hyg. 1995;53:547\u201351.","journal-title":"Am J Trop Med Hyg"},{"key":"4267_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00717727","volume":"18","author":"NS Postma","year":"1996","unstructured":"Postma NS, Mommers EC, Eling WM, Zuidema J. Oxidative stress in malaria; implications for prevention and therapy. Pharm World Sci. 1996;18:121\u20139.","journal-title":"Pharm World Sci"},{"key":"4267_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.638885","volume":"12","author":"G Bancone","year":"2021","unstructured":"Bancone G, Chu CS. G6PD variants and haemolytic sensitivity to primaquine and other drugs. Front Pharmacol. 2021;12: 638885.","journal-title":"Front Pharmacol"},{"key":"4267_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2019.105252","volume":"202","author":"RS Bharti","year":"2020","unstructured":"Bharti RS, Vashisht K, Ahmed N, Nayak A, Pande V, Mishra N. First report of glucose-6-phosphate dehydrogenase (G6PD) variants (Mahidol and Acores) from malaria-endemic regions of northeast India and their functional evaluations in-silico. Acta Trop. 2020;202: 105252.","journal-title":"Acta Trop"},{"key":"4267_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ymgme.2016.03.008","volume":"118","author":"U Boonyuen","year":"2016","unstructured":"Boonyuen U, Chamchoy K, Swangsri T, Saralamba N, Day NP, Imwong M. Detailed functional analysis of two clinical glucose-6-phosphate dehydrogenase (G6PD) variants, G6PDViangchan and G6PDViangchan+Mahidol: decreased stability and catalytic efficiency contribute to the clinical phenotype. Mol Genet Metab. 2016;118:84\u201391.","journal-title":"Mol Genet Metab"},{"key":"4267_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.12688\/wellcomeopenres.15100.1","volume":"4","author":"CS Chu","year":"2019","unstructured":"Chu CS, Bancone G, Soe NL, Carrara VI, Gornsawun G, Nosten F. The impact of using primaquine without prior G6PD testing: a case series describing the obstacles to the medical management of haemolysis. Wellcome Open Res. 2019;4:25.","journal-title":"Wellcome Open Res"},{"key":"4267_CR45","volume-title":"World Malaria Report 2017","author":"WHO","year":"2017","unstructured":"WHO. World Malaria Report 2017. Geneva: World Health Organization; 2017."},{"key":"4267_CR46","volume-title":"Updated WHO Policy Recommendation: single dose primaquine as a gametocytocide in Plasmodium falciparum malaria","author":"WHO","year":"2012","unstructured":"WHO. Updated WHO Policy Recommendation: single dose primaquine as a gametocytocide in Plasmodium falciparum malaria. Geneva: World Health Organization; 2012."},{"key":"4267_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151898","volume":"11","author":"G Bancone","year":"2016","unstructured":"Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, et al. Single low dose primaquine (0.25 mg\/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS ONE. 2016;11: e0151898.","journal-title":"PLoS ONE"},{"key":"4267_CR48","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12879-019-3862-1","volume":"19","author":"L Dysoley","year":"2019","unstructured":"Dysoley L, Kim S, Lopes S, Khim N, Bjorges S, et al. The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians. BMC Infect Dis. 2019;19:250.","journal-title":"BMC Infect Dis"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04267-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04267-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04267-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T04:03:09Z","timestamp":1661832189000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04267-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4267"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04267-7","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"18 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (COA No. 040\/2013 IRB No. 459\/55). The protocol of this study was performed according to the Declaration of Helsinki for the participation of human individuals. Written informed consent was obtained from each participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"250"}}